Restricted accessResearch articleFirst published online 2026-4
Microbiota,Gender-Affirming Hormone Therapy,and Inflammatory Biomarkers in Transgender Women with HIV: Potential Implications for Cardiovascular Disease
The intersecting disparities of human immunodeficiency virus (HIV) and cardiovascular disease (CVD) among transgender women have raised questions about the role of the gut microbiota and gender-affirming hormone therapy (GAHT) in the pathogenesis of CVD in the context of HIV. The purpose of this study was to provide an early exploration of the associations between these possible mechanisms driving inflammatory CVD risk markers among transgender women with HIV.
Methods:
We conducted a preliminary study with 21 transgender women with HIV exploring the relationship between GAHT use (self-report), gut/rectal microbiota composition (rectal swabs), and inflammatory markers linked to CVD (plasma). Microbiota measures included alpha (richness, evenness, and Shannon diversity) and beta (Bray–Curtis, un/weighted UniFrac) diversity metrics. Inflammatory biomarkers included intestinal fatty-acid binding protein, monocyte chemoattractant protein-1, soluble CD163, intercellular adhesion molecule 1, tumor necrosis factor alpha (TNFa), soluble TNF receptor I (sTNF-I), sTNF-II, interleukin (IL)-6, IL-8, IL-1b, IL-1a, soluble CD14, d-dimer (domain dimer), vascular cell adhesion molecule 1, and high-sensitivity C-reactive protein. Wilcoxon rank sum test, log-level regression, Spearman’s rho, permutational multivariate analysis of variance, and differential abundance testing assessed relationships between constructs.
Results:
Key inflammatory markers linked to CVD were associated with GAHT use—an increased sTNF-I and sTNF-II levels and decreased IL-1a levels. Microbiota composition was not related to GAHT use but was variably associated with inflammatory biomarkers related to CVD risk.
Conclusions:
Although preliminary, these findings suggest a potential association between inflammation linked to CVD risk and microbiota composition and GAHT. The results contribute to the characterization of interconnecting factors that may inform understanding and interventions to enhance overall health and well-being in transgender women with HIV. Further research is essential to elucidate the mechanisms underlying these associations, ultimately striving for health equity.
BaralSD, PoteatT, StromdahlS, et al.Worldwide burden of HIV in transgender women: A systematic review and meta-analysis. Lancet Infect Dis, 2013; 13(3):214–222; doi: 10.1016/S1473-3099(12)70315-8
2.
KalichmanSC, HernandezD, FinneranS, et al.Transgender women and HIV-related health disparities: Falling off the HIV treatment cascade. Sex Health, 2017; 14(5):469–476; doi: 10.1071/sh17015
3.
StreedCG, BeachLB, CaceresBA, et al.American Heart Association Council on Peripheral Vascular Disease; Council on Arteriosclerosis, Thrombosis and Vascular Biology; Council on Cardiovascular and Stroke Nursing; Council on Cardiovascular Radiology and Intervention; Council on Hypertension; and Stroke Council. Assessing and addressing cardiovascular health in people who are transgender and gender diverse: A scientific statement from the American heart association. Circulation, 2021; 144(6):e136–e148; doi: 10.1161/CIR.0000000000001003
4.
Centers for Disease Control and Prevention. HIV infection, risk, prevention, and testing behaviors among transgender women - national HIV behavioral surveillance, 7 U.S. Cities, 2019-2020. Surveillance special report 27. National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention: Atlanta, GA; 2021.
5.
StutterheimSE, van DijkM, WangH, et al.The worldwide burden of HIV in transgender individuals: An updated systematic review and meta-analysis. PLoS One, 2021; 16(12):e0260063; doi: 10.1371/journal.pone.0260063
6.
GetahunD, NashR, FlandersWD, et al.Cross-sex hormones and acute cardiovascular events in transgender persons: A cohort study. Ann Intern Med, 2018; 169(4):205–213; doi: 10.7326/m17-2785
7.
GosikerBJ, LeskoCR, RichAJ, et al.Cardiovascular disease risk among transgender women living with HIV in the United States. PLoS One, 2020; 15(7):e0236177; doi: 10.1371/journal.pone.0236177
8.
Lacombe-DuncanA, WarrenL, KayES, et al.Mental health among transgender women living with HIV in Canada: Findings from a national community-based research study. AIDS Care, 2021; 33(2):192–200; doi: 10.1080/09540121.2020.1737640
9.
WilligAL, WebelAR, WestfallAO, et al.Physical activity trends and metabolic health outcomes in people living with HIV in the US, 2008–2015. Prog Cardiovasc Dis, 2020; 63(2):170–177; doi: 10.1016/j.pcad.2020.02.005
10.
HughtoJMW, QuinnEK, DunbarMS, et al.Prevalence and co-occurrence of alcohol, nicotine, and other substance use disorder diagnoses among us transgender and cisgender adults. JAMA Netw Open, 2021; 4(2):e2036512; doi: 10.1001/jamanetworkopen.2020.36512
11.
DillonSM, FrankDN, WilsonCC. The gut microbiome and HIV-1 pathogenesis: A two-way street. Aids, 2016; 30(18):2737–2751; doi: 10.1097/QAD.0000000000001289
12.
KlattNR, ChomontN, DouekDC, et al.Immune activation and HIV persistence: Implications for curative approaches to HIV infection. Immunol Rev, 2013; 254(1):326–342; doi: 10.1111/imr.12065
13.
KlattNR, FunderburgNT, BrenchleyJM. Microbial translocation, immune activation, and HIV disease. Trends Microbiol, 2013; 21(1):6–13; doi: 10.1016/j.tim.2012.09.001
14.
BurgenerA, McGowanI, KlattNR. HIV and mucosal barrier interactions: Consequences for transmission and pathogenesis. Curr Opin Immunol, 2015; 36:22–30; doi: 10.1016/j.coi.2015.06.004
15.
Vujkovic-CvijinI, DunhamRM, IwaiS, et al.Dysbiosis of the gut microbiota is associated with HIV disease progression and tryptophan catabolism. Sci Transl Med, 2013; 5(193):193ra91; doi: 10.1126/scitranslmed.3006438
16.
CrakesKR, JiangG. Gut microbiome alterations during HIV/SIV infection: Implications for HIV cure. Front Microbiol, 2019; 10:1104; doi: 10.3389/fmicb.2019.01104
17.
ForkoshE, IlanY. The heart-gut axis: New target for atherosclerosis and congestive heart failure therapy. Open Heart, 2019; 6(1):e000993; doi: 10.1136/openhrt-2018-000993
18.
LeslieJL, AnnexBH. The microbiome and endothelial function. Circ Res, 2018; 123(9):1015–1016; doi: 10.1161/CIRCRESAHA.118.313813
19.
PengJ, XiaoX, HuM, et al.Interaction between gut microbiome and cardiovascular disease. Life Sci, 2018; 214:153–157; doi: 10.1016/j.lfs.2018.10.063
20.
AhmadAF, WardNC, DwivediG. The gut microbiome and heart failure. Curr Opin Cardiol, 2019; 34(2):225–232; doi: 10.1097/HCO.0000000000000598
21.
Cavalcanti NetoMP, AquinoJS, Romao da SilvaLF, et al.Gut microbiota and probiotics intervention: A potential therapeutic target for management of cardiometabolic disorders and chronic kidney disease? Pharmacol Res, 2018; 130:152–163; doi: 10.1016/j.phrs.2018.01.020
22.
KatsiV, DidagelosM, SkevofilaxS, et al.Gut microbiome-gut dysbiosis-arterial hypertension: New horizons. Curr Hypertens Rev, 2019; 15(1):40–46; doi: 10.2174/1573402114666180613080439
23.
LiuYW, LiongMT, TsaiYC. New perspectives of lactobacillus plantarum as a probiotic: The gut-heart-brain axis. J Microbiol, 2018; 56(9):601–613; doi: 10.1007/s12275-018-8079-2
24.
OnalEM, AfsarB, CovicA, et al.Gut microbiota and inflammation in chronic kidney disease and their roles in the development of cardiovascular disease. Hypertens Res, 2019; 42(2):123–140; doi: 10.1038/s41440-018-0144-z
25.
ConklinDJ, SchickS, BlahaMJ, et al.Cardiovascular injury induced by tobacco products: Assessment of risk factors and biomarkers of harm. Am J Physiol Heart Circ Physiol, 2019; 316(4):H801–H827; doi: 10.1152/ajpheart.00591.2018
26.
GilbertJA, BlaserMJ, CaporasoJG, et al.Current understanding of the human microbiome. Nat Med, 2018; 24(4):392–400; doi: 10.1038/nm.4517
27.
GrantJM, MottetLA, TanisJ, et al.National Transgender Discrimination Survey Report on Health and Health Care. National Center for Transgender Equality and National Gay and Lesbian Task Force: Washington, DC; 2010.
28.
StreedCGJr, HarfouchO, MarvelF, et al.Cardiovascular disease among transgender adults receiving hormone therapy: A narrative review. Ann Intern Med, 2017; 167(4):256–267; doi: 10.7326/M17-0577
29.
MartinezC, RikhiR, HaqueT, et al.Gender identity, hormone therapy, and cardiovascular disease risk. Curr Probl Cardiol, 2020; 45(5):100396; doi: 10.1016/j.cpcardiol.2018.09.003
30.
ShinJ-H, ParkYH, SimM, et al.Serum level of sex steroid hormone is associated with diversity and profiles of human gut microbiome. Res Microbiol, 2019; 170(4–5):192–201; doi: 10.1016/j.resmic.2019.03.003
31.
MaffeiS, ForiniF, CanaleP, et al.Gut microbiota and sex hormones: Crosstalking players in cardiometabolic and cardiovascular disease. Ijms, 2022; 23(13):7154.
32.
OrgE, MehrabianM, ParksBW, et al.Sex differences and hormonal effects on gut microbiota composition in mice. Gut Microbes, 2016; 7(4):313–322; doi: 10.1080/19490976.2016.1203502
33.
NotaNM, WiepjesCM, de BlokCJM, et al.Occurrence of acute cardiovascular events in transgender individuals receiving hormone therapy. Circulation, 2019; 139(11):1461–1462; doi: 10.1161/CIRCULATIONAHA.118.038584
34.
GoorenLJ, WierckxK, GiltayEJ. Cardiovascular disease in transsexual persons treated with cross-sex hormones: Reversal of the traditional sex difference in cardiovascular disease pattern. Eur J Endocrinol, 2014; 170(6):809–819; doi: 10.1530/EJE-14-0011
35.
MartinezCA, RikhiR, Fonseca NogueiraN, et al.Estrogen-based gender-affirming hormone therapy and subclinical cardiovascular disease in transgender women with HIV. LGBT Health, 2023; 10(8):576–585; doi: 10.1089/lgbt.2023.0010
36.
GohlDM, VangayP, GarbeJ, et al.Systematic improvement of amplicon marker gene methods for increased accuracy in microbiome studies. Nat Biotechnol, 2016; 34(9):942–949; doi: 10.1038/nbt.3601
37.
CallahanBJ, McMurdiePJ, RosenMJ, et al.DADA2: High-resolution sample inference from illumina amplicon data. Nat Methods, 2016; 13(7):581–583; doi: 10.1038/nmeth.3869
38.
BokulichNA, ZiemskiM, RobesonMS, et al.Measuring the microbiome: Best practices for developing and benchmarking microbiomics methods. Comput Struct Biotechnol J, 2020; 18:4048–4062; doi: 10.1016/j.csbj.2020.11.049
39.
AlcaideML, ParmigianiA, PallikkuthS, et al.Immune activation in HIV-infected aging women on antiretrovirals–implications for age-associated comorbidities: A cross-sectional pilot study. PLoS One, 2013; 8(5):e63804; doi: 10.1371/journal.pone.0063804
40.
BahramiH, BudoffM, HaberlenSA, et al.Inflammatory markers associated with subclinical coronary artery disease: The multicenter AIDS cohort study. J Am Heart Assoc, 2016; 5(6):e003371; doi: 10.1161/JAHA.116.003371
41.
BenjaminiY, HochbergY. Controlling the false discovery rate: A practical and powerful approach to multiple testing. J R Stat Soc Series B Stat Methodol, 1995; 57(1):289–300; doi: 10.1111/j.2517-6161.1995.tb02031.x
42.
LoveMI, HuberW, AndersS. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol, 2014; 15(12):550; doi: 10.1186/s13059-014-0550-8
43.
McPhersonGW, GoldsteinZ, SalipanteSJ, et al.The vaginal microbiome of transgender and gender nonbinary individuals. Transgend Health, 2024; 9(3):205–211; doi: 10.1089/trgh.2022.0100
44.
LacunzaE, FinkV, SalasME, et al.Oral and anal microbiome from HIV-exposed individuals: Role of host-associated factors in taxa composition and metabolic pathways. NPJ Biofilms Microbiomes, 2023; 9(1):48; doi: 10.1038/s41522-023-00413-4
45.
PetersBA, SantoroN, KaplanRC, et al.Spotlight on the gut microbiome in menopause: Current insights. Int J Womens Health, 2022; 14:1059–1072; doi: 10.2147/ijwh.S340491
46.
d’AfflittoM, UpadhyayaA, GreenA, et al.Association between sex hormone levels and gut microbiota composition and diversity-a systematic review. J Clin Gastroenterol, 2022; 56(5):384–392; doi: 10.1097/mcg.0000000000001676
47.
CutoloM, SulliA, CapellinoS, et al.Anti-TNF and sex hormones. Ann N Y Acad Sci, 2006; 1069:391–400; doi: 10.1196/annals.1351.037
48.
DeBoerMD, ThayuM, GriffinLM, et al.Increases in sex hormones during anti-tumor necrosis factor α therapy in adolescents with Crohn’s disease. J Pediatr, 2016; 171:146–152.e1-2; doi: 10.1016/j.jpeds.2016.01.003
49.
BenjafieldAV, WangXL, MorrisBJ. Tumor necrosis factor receptor 2 gene (TNFRSF1B) in genetic basis of coronary artery disease. J Mol Med (Berl), 2001; 79(2–3):109–115; doi: 10.1007/s001090000168
50.
CarlssonAC, RugeT, KjøllerE, et al.10‐year associations between tumor necrosis factor receptors 1 and 2 and cardiovascular events in patients with stable coronary heart disease: A CLARICOR trial substudy. Jaha, 2018; 7(9):e008299; doi: 10.1161/JAHA.117.008299
51.
CarlssonAC, JuhlinCC, LarssonTE, et al.Soluble tumor necrosis factor receptor 1 (sTNFR1) is associated with increased total mortality due to cancer and cardiovascular causes – findings from two community based cohorts of elderly. Atherosclerosis, 2014; 237(1):236–242.
52.
SchutteMH, KleemannR, NotaNM, et al.The effect of transdermal gender-affirming hormone therapy on markers of inflammation and hemostasis. PLoS One, 2022; 17(3):e0261312; doi: 10.1371/journal.pone.0261312
53.
MorishitaM, MiyagiM, IwamotoY. Effects of sex hormones on production of interleukin-1 by human peripheral monocytes. J Periodontol, 1999; 70(7):757–760; doi: 10.1902/jop.1999.70.7.757
54.
ZafarH, SaierMHJr. Gut Bacteroides species in health and disease. Gut Microbes, 2021; 13(1):1–20; doi: 10.1080/19490976.2020.1848158
55.
YoonK, KimN. Roles of sex hormones and gender in the gut microbiota. J Neurogastroenterol Motil, 2021; 27(3):314–325; doi: 10.5056/jnm20208
56.
MartínR, Rios-CovianD, HuilletE, et al.Faecalibacterium: A bacterial genus with promising human health applications. FEMS Microbiol Rev, 2023; 47(4):fuad039; doi: 10.1093/femsre/fuad039
57.
VerstraetenS, SencioV, RaiseA, et al.Description of a newly isolated blautia faecis strain and its benefit in mouse models of post-influenza secondary enteric and pulmonary infections. Nutrients, 2022; 14(7):1478; doi: 10.3390/nu14071478
58.
Al ShehriD, SaadahOI, MosliM, et al.Compositional and functional alteration of gut microbiota profiles in response to anti-TNF-α therapy in inflammatory bowel disease: A pilot study. Imu, 2024; 44:101415; doi: 10.1016/j.imu.2023.101415
59.
BiagiE, NylundL, CandelaM, et al.Through ageing, and beyond: Gut microbiota and inflammatory status in seniors and centenarians. PLoS One, 2010; 5(5):e10667; doi: 10.1371/journal.pone.0010667
60.
NovakovicM, RoutA, KingsleyT, et al.Role of gut microbiota in cardiovascular diseases. World J Cardiol, 2020; 12(4):110–122; doi: 10.4330/wjc.v12.i4.110
61.
ZhangY, WangY, KeB, et al.TMAO: How gut microbiota contributes to heart failure. Transl Res, 2021; 228:109–125; doi: 10.1016/j.trsl.2020.08.007
62.
ChambersES, PrestonT, FrostG, et al.Role of gut microbiota-generated short-chain fatty acids in metabolic and cardiovascular health. Curr Nutr Rep, 2018; 7(4):198–206; doi: 10.1007/s13668-018-0248-8
63.
Yukino-IwashitaM, NagatomoY, KawaiA, et al.Short-chain fatty acids in gut-heart axis: Their role in the pathology of heart failure. J Pers Med, 2022; 12(11):1805; doi: 10.3390/jpm12111805
64.
WuHJ, WuE. The role of gut microbiota in immune homeostasis and autoimmunity. Gut Microbes, 2012; 3(1):4–14; doi: 10.4161/gmic.19320
65.
TsalamandrisS, AntonopoulosAS, OikonomouE, et al.The role of inflammation in diabetes: Current concepts and future perspectives. Eur Cardiol, 2019; 14(1):50–59; doi: 10.15420/ecr.2018.33.1
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
